Last reviewed · How we verify
HER2 Tumor Vaccine
HER2 Tumor Vaccine is a Biologic drug developed by The First Affiliated Hospital of Bengbu Medical University. It is currently in Phase 1 development.
At a glance
| Generic name | HER2 Tumor Vaccine |
|---|---|
| Sponsor | The First Affiliated Hospital of Bengbu Medical University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site reaction
- Pruritus
- Skin induration
- Fatigue
- Other, specify
- Headache
- Arthralgia
- Pain
- Myalgia
- Nausea
- Back pain
- Chills
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (PHASE1)
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
- A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (PHASE2)
- Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (PHASE3)
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer (PHASE2)
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (PHASE1, PHASE2)
- Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HER2 Tumor Vaccine CI brief — competitive landscape report
- HER2 Tumor Vaccine updates RSS · CI watch RSS
- The First Affiliated Hospital of Bengbu Medical University portfolio CI
Frequently asked questions about HER2 Tumor Vaccine
What is HER2 Tumor Vaccine?
HER2 Tumor Vaccine is a Biologic drug developed by The First Affiliated Hospital of Bengbu Medical University.
Who makes HER2 Tumor Vaccine?
HER2 Tumor Vaccine is developed by The First Affiliated Hospital of Bengbu Medical University (see full The First Affiliated Hospital of Bengbu Medical University pipeline at /company/the-first-affiliated-hospital-of-bengbu-medical-university).
What development phase is HER2 Tumor Vaccine in?
HER2 Tumor Vaccine is in Phase 1.
What are the side effects of HER2 Tumor Vaccine?
Common side effects of HER2 Tumor Vaccine include Injection site reaction, Pruritus, Skin induration, Fatigue, Other, specify, Headache.